Archives

5 March 2021 ASX ANNOUNCEMENT Appointment of Non-Executive Director – Mary Sontrop Medical Developments International Limited (ASX: MVP) is pleased to announce the appointment of Ms. Mary Sontrop as a Non-Executive Director of the Company with immediate effect. Mary has extensive international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration.  During […]

26 February 2021 ASX ANNOUNCEMENT Medical Developments International Limited (ASX:MVP) has today released its FY21 Half Year Report and Accounts. Please click on the following link to view the release – FY21 HY Report and Accounts  

14 December 2020 ASX ANNOUNCEMENT Medical Developments completes a A$25 million placement to accelerate the commercialisation of Penthrox in European Markets Please refer to the attached for the full announcements – MVP – ASX Announcement – Completion of Placement Please also refer to the related Investor Presentation – MVP Investor Presentation

3 December 2020 ASX ANNOUNCEMENT EU Transition and Trading Update Medical Developments International Limited (ASX: MVP) today provides an update in relation to its Penthrox EU transition activities and trading conditions. Transition arrangements for taking back the distribution rights from Mundipharma in the EU are progressing to plan.  Progress to date includes the establishment of […]

3 December 2020 ASX ANNOUNCEMENT MVP Board Re-organisation Medical Developments International Limited (ASX: MVP) today announces that Gordon Naylor will assume the position of Non-Executive Chairman effective from December 18th, succeeding David Williams who has held the role since the company was first listed in December 2003.  Mr Williams will continue to serve on the […]

30 October 2020 ASX ANNOUNCEMENT MVP and MundiPharma agree to cease distribution and licensing agreement in Australia MVP today announced it has taken back the distribution rights for its pain relief drug Penthrox in the Australian market from MundiPharma. Since assigning the rights to Mundipharma a year ago, the global Mundipharma organisation has gone through […]

28 October 2020 ASX ANNOUNCEMENT Chairman’s and CEO’s Address to Shareholders Medical Developments International Limited today held its 2020 Annual General Meeting.  The AGM Chairman and CEO address to shareholders is contained in the following link – ASX Announcement – Chairman’s and CEO’s Address to Shareholders

14 October 2020 ASX ANNOUNCEMENT Appointment of Chief Executive Officer – Brent MacGregor Medical Developments International Limited (ASX: MVP) is delighted to announce the appointment of Brent MacGregor as Chief Executive Officer of the Company from 1 November 2020.  The key terms of his employment are an attachment to this announcement. Refer to the following […]

19 August 2020 ASX ANNOUNCEMENT Head of Europe Appointed Medical Developments International (ASX: MVP) is pleased to announce the appointment of Mr Stefaan Schatteman as Head of its European business effective immediately. Stefaan will lead the Company’s direct push into the 27 member states in the EU and Switzerland. Stefaan is a 15-year veteran of […]

19 August 2020 ASX ANNOUNCEMENT Medical Developments to take control of EU markets Medical Developments International (ASX: MVP) today announced it has reached in principle agreement to enter into a contract with the Mundipharma network in Europe to take back the distribution rights for its pain relief drug, Penthrox® in all 27 member states in […]